Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted Income from Continuing Operations of $1.1 billion for Q2 2026, up 6.63% on a QoQ basis from $1.0 billion in Q1 2026, and up 6.48% year-over-year from $1.0 billion in Q2 2025.
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals has reported Income from Continuing Operations for 18 years, with the latest figure at $1.1 billion in Q2 2026.
- On a quarterly basis, Income from Continuing Operations rose 6.48% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $4.4 billion, a 21.1% increase from a year earlier, with the FY2025 full-year figure at $4.0 billion, up 838.09% from the prior year.
- Income from Continuing Operations was $1.1 billion for Q2 2026 at Vertex Pharmaceuticals, up from $1.0 billion in the prior quarter.
- The five-year high for Income from Continuing Operations was $1.2 billion in Q4 2025, with the low at -$3.6 billion in Q2 2024.
- Average Income from Continuing Operations over 5 years is $693.9 million, with a median of $949.6 million recorded in 2022.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations soared 1109.7% in 2022, then slumped 492.44% in 2024.
- Over 5 years, Income from Continuing Operations stood at $818.9 million in 2022, then rose by 18.31% to $968.8 million in 2023, then slipped by 5.76% to $913.0 million in 2024, then surged by 30.46% to $1.2 billion in 2025, then dropped by 7.67% to $1.1 billion in 2026.
- The last three Income from Continuing Operations figures came in at $1.1 billion (Q2 2026), $1.0 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Bristol Myers Squibb | 124.95 Bn | 113.89 Bn | 9.25 Bn | 3.32 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Bn |
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 1.19 Bn |
| Sep 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 646.30 Mn |
| Dec 31, 2024 | 913.00 Mn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | -3.59 Bn |
| Mar 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 968.80 Mn |
| Sep 30, 2023 | 1.04 Bn |
| Jun 30, 2023 | 915.70 Mn |
| Mar 31, 2023 | 699.80 Mn |
| Dec 31, 2022 | 818.90 Mn |
| Sep 30, 2022 | 930.50 Mn |
| Jun 30, 2022 | 810.50 Mn |
| Mar 31, 2022 | 762.10 Mn |
| Dec 31, 2021 | 770.10 Mn |
| Sep 30, 2021 | 851.90 Mn |
API Access
Vertex Pharmaceuticals Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=VRTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "VRTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=VRTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();